ComboMATCH Screening Trial
Phase 2
2,900
about 7.2 years
All ages
476 sites in AK, AL, AR +41
About this study
This trial is testing a new way to treat cancer by matching it to the patient's unique genetic makeup. The goal of this screening trial is to identify patients who might benefit from targeted therapies based on their tumor's specific genetic mutations. It aims to find treatments that could control tumors and help doctors plan better treatment for people with locally advanced or advanced solid tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Panitumumab
- 2.Take Alpelisib
- 3.Take Binimetinib
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
alpelisib, binimetinib, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), fulvestrant, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), Antineoplastic Agent [TC] (Kinase Inhibitors), Antineoplastic Agent [TC] (Bcr-Abl Tyrosine Kinase Inhibitors), olaparib
oral (Oral Tablet), oral (Oral Capsule), injection, injection (Injection), oral, intravenous
biopsy, diagnostic, imaging
Oncology